JPRN-UMIN000034205已完成未知
An investigator-initiated, multicenter, phase II study to determine the efficacy and safety of brentuximab vedotin in patients with relapsed or refractory CD30-positive cutaneous T-Cell lymphoma - An investigator-initiated, multicenter, phase II study to determine the efficacy and safety of brentuximab vedotin in patients with relapsed or refractory CD30-positive cutaneous T-Cell lymphoma
Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences0 个研究点目标入组 15 人开始时间: 2019年1月1日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 15
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1.Patients with concurrent systemic ALCL 2.Patients with concurrent Sezary syndrome or B2 disease 3.Patients with any of the following cardiovascular conditions or test values within 6 months before enrollment a.Myocardial infarction. b.New York Heart Association Class 3 or 4 heart failure c.Any uncontrolled cardiovascular conditions 4.Patients with a history of another primary malignancy not in remission for at least 3 years. 5.Patients with known active cerebral meningeal disease, including signs or symptoms of progressive multifocal leukoencephalopathy 6.Patients with known HIV infection 7.Patients with known hepatitis B surface antigen positivity or known or suspected active hepatitis C infection 8.Patients with any severe active systemic viral, bacterial, or fungal infection requiring systemic treatment before the start of study drug administration. 9.Patients who received antibody directed or immunoglobulin based immune therapy within 12 weeks before study drug administration 10.Patients who received corticosteroid therapy for the treatment of CTCL within 3 weeks before study drug administration 11.Patients with known hypersensitivity to recombinant proteins, murine proteins, or any excipient contained in the drug formulation 12.Female patients who are pregnant or breastfeeding, or have a positive serum pregnancy test during the screening period or a positive urine pregnancy test on Day 1 of any cycle 13.Patients who received treatment with radiotherapy, other skin directed therapy, or any investigational drug within 3 weeks before study drug administration 14.Patients with pancreatitis or significant risk factors for developing pancreatitis 15.Patients who previously received brentuximab vedotin before this study 16.Other patients judged by the investigator or subinvestigator to be inappropriate for participation in this study
研究者
相似试验
已完成
2 期
A multicenter, investigator-initiated phase II clinical trial involving administration of a cross-linked gelatin hydrogel containing recombinant human basic fibroblast growth factor (rh-bFGF) to prevent the collapse of the femoral headOsteonecrosis of the femoral headJPRN-UMIN000020340Haruhiko Akiyama, Gifu University Hospital64
进行中（未招募）
1 期
An Investigator-Initiated, Phase II, Multicenter, Open-Label, Single-Arm, Prospective Clinical Trial to Evaluate the Efficacy and Safety of Alternating Bortezomib-Based Regimens in Combination with DaratUMumab followed by Maintenance with Daratumumab in the Frontline Setting of Primary Plasma CEll LEukemIA: A Trial of the Greek Myeloma Study GroupPrimary plasma cell leukemiaMedDRA version: 20.0Level: LLTClassification code 10035223Term: Plasma cell leukemiaSystem Organ Class: 100000004864EUCTR2021-001990-22-GRHellenic Society of Haematology (HSH)43
已完成
2 期
The Hunter Humira and Endothelial Function in Early Rheumatoid Arthritis TrialMusculoskeletal - Other muscular and skeletal disordersCardiovascular - Diseases of the vasculature and circulation including the lymphatic systemInflammatory and Immune System - Rheumatoid arthritisCardiovascular DiseaseRheumatoid ArthritisACTRN12611000972921A/Prof Stephen Oakley60
进行中（未招募）
2 期
A Phase II, Multi-Center, Investigator-Initiated Study of Dasatinib against AITL and Other T Follicular Helper Cell LymphomaRelapsed/refractory T Follicular Helper Cell LymphomaJPRN-jRCT2031190079Chiba Shigeru18
招募中
2 期
Phase IIb investigator-initiated multicenter study of the efficacy and safety of intravenous HUCV002-01 in patients with chronic heart failure (continuous study)chronic heart failureJPRN-jRCT2073220002Tsutsui Hiroyuki15